Phase 2 feasibility study of adjuvant chemotherapy with cisplatin (CDDP) and TS-1, followed by alternate-day TS-1 maintenance therapy, in patients with completely resected pathological stage II-IIIA non-small cell lung cancer.

ABSTRACT:

Background

Platinum-based doublet chemotherapy is recommended as the standard adjuvant treatment for completely resected stage II/III non-small cell lung cancer (NSCLC). Among these regimens, cisplatin plus vinorelbine (CDDP + VNR) has been most frequently used in Japan and shown to improve survival, but it is associated with significant toxicity that often limits treatment completion. In contrast, TS-1, an oral fluoropyrimidine combined with CDDP, has demonstrated potential as a less toxic alternative. This phase 2 study aimed to assess the feasibility, safety, and efficacy of CDDP plus TS-1 (CDDP + TS-1) followed by TS-1 monotherapy as an adjuvant treatment for patients with completely resected stage II-III NSCLC.

Methods

This prospective, multicenter, phase 2 study enroll

SUBMITTER: Fujino K 

PROVIDER: S-EPMC12688522 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature